TLRY Tilray

Tilray Renews Distribution Agreement With Great North Distributors for Cannabis Sales Across Canada With Newly Expanded Brand Portfolio

Tilray Renews Distribution Agreement With Great North Distributors for Cannabis Sales Across Canada With Newly Expanded Brand Portfolio

Tilray Continues to Lead Cannabis Market Share Across Canada

LEAMINGTON, Ontario, July 27, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company and Great North Distributors, Inc. (Great North), Canada’s leading national sales broker for legalized adult-use cannabis — today announced a renewed national brokerage agreement. Under the agreement, Great North will continue to be the exclusive representative for Tilray’s full portfolio of recreational cannabis products across the Canadian marketplace, with the exception of Quebec. Tilray’s market-leading cannabis portfolio includes Good Supply, RIFF, Solei, Canaca, The Batch, Chowie Wowie, and newly acquired Redecan, Original Stash, and Bake Sale.

Per the renewed 4-year agreement, Great North will invest significant, dedicated, incremental headcount to the Tilray division across all provinces and territories, upgrading key account resources, brand education for budtenders, and enhanced data capabilities to assist retailers in making the best possible decisions to maximize sales revenue.

“As the Canadian cannabis retail landscape continues to evolve, continuity in our distributor allows us to capture significant synergies and further optimize our national sales strategy. Our renewed agreement will further drive exceptional route-to-market efficiencies for our market-leading and growing cannabis portfolio which now includes HEXO brands,” said, Blair MacNeil, President, Tilray Canada. “Great North’s national Canadian network is best positioned to help us accelerate growth and capture even more market share across Canada. As we continue to build our brands, our longstanding relationship with Great North provides us with the flexibility to adjust to market conditions in real time.”

“Securing the trust of Tilray cements our cannabis sales leadership position in Canada,” said Doug Wieland, President, Great North Distributors. “Great North has executed in the Canadian cannabis market since day one and will continue to bring sales execution excellence to Tilray and now Hexo portfolio of brands. Additionally, we are investing resources to bring market-leading brand education and activation to our retail partners to support them in achieving their revenue and profit goals."

Great North has an extensive reach across every province in Canada, including established relationships and expertise working with provincially owned and operated retailers and private retailers in Canada’s cannabis industry. Great North applies industry-leading data analytics capabilities to the sector, providing suppliers with a powerful data-driven approach to cannabis sales.

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Tilray’s mission is to be the most responsible, trusted, and market-leading cannabis and consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray Brands, visit and follow @tilray on all social platforms.

About Great North Distributors

Great North Distributors, Inc., established as a joint venture by the owners of Southern Glazer’s Wine & Spirits, is Canada’s first national sales broker for legalized adult-use cannabis. Great North Distributors has reach across every province in Canada, including established relationships and expertise working with provincially owned and operated retailers and private retailers alike. Great North applies industry-leading data analytics capabilities from the wine and spirits industry to the new cannabis industry, providing suppliers with a powerful data-driven approach to cannabis sales. For more information visit .

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information:

Media: Berrin Noorata,

Investors: Raphael Gross, (203) 682-8253,  



EN
27/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tilray

 PRESS RELEASE

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich...

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich durch eine strategische Vereinbarung mit Smartway Pharmaceuticals CC-Pharma-Vereinbarung fördert das Wachstum von Tilray im Vereinigten Königreich und stärkt den Vertrieb über Apotheken- und Krankenhauskanäle NEW YORK und LONDON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass ihr europäisches pharmazeutisches Vertriebsunternehmen CC Pharma eine strategische Vereinbarung mit , einem führenden pharmazeutischen Vertriebspartner...

 PRESS RELEASE

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni g...

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la division pharmaceutique de Tilray Brands, Inc. (Nasdaq : TLRY ; TSX : TLRY), a annoncé aujourd'hui que son activité de distribution pharmaceutique européenne, CC Pharma, a conclu un accord stratégique avec , un partenaire de distribution pharmaceutique...

 PRESS RELEASE

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement wi...

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals CC Pharma Agreement Bolsters Tilray’s UK Growth, Strengthening Distribution to Pharmacy and Hospital Channels NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with , a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products...

 PRESS RELEASE

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in De...

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in Deutschland ausgezeichnet Die Auszeichnung würdigt CC Pharma als innovativen Marktführer und vertrauenswürdigen Partner auf dem europäischen Pharmamarkt DENSBORN, Deutschland, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass , ihr europäischer Pharmahändler, zu einem der ernannt wurde. Hierbei handelt es sich um eine der renommiertesten und unabhängigsten Auszeichnungen für Innovation bei kleinen und mittleren Unternehmen des La...

 PRESS RELEASE

CC Pharma, filiale de Tilray, figure parmi le classement TOP 100 Innov...

CC Pharma, filiale de Tilray, figure parmi le classement TOP 100 Innovator en Allemagne Cette distinction récompense CC Pharma dans son rôle de leader de l’innovation et de partenaire de référence du marché pharmaceutique européen DENSBORN, Allemagne, 04 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la division pharmaceutique de Tilray Brands, Inc. (Nasdaq : TLRY ; TSX : TLRY), a annoncé aujourd’hui que , son entreprise européenne de distribution pharmaceutique, a été nommée au , l’une des distinctions indépendantes les plus prestigieuses du pays en matière d’innovation parmi les petite...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch